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utilization in healthy humans under insulin-stimulated condi
tions (1). This study develops and evaluates an experimental
method to quantify the two initial steps of muscular glucose
metabolism in vivo. These two steps can be quantitatively
assessed by 2-[18fl-fluoro-2-deoxy-D-glucose (FDG). FDG
is a radioactive glucose analog that is transported across the
cell membrane into the muscle cell and phosphorylated
intracellularly by the enzyme hexokinase to FDG-6-
phosphate (FDG-6-P). FDG-6-P does not further participate
in the cascade of glucose metabolism and accumulates
inside the cell because intracellular glucose-6-phosphatase
activity is low in brain and muscle (2). Measurement of
tissue FDG accumulation by PET has therefore been used to
quantify regional glucose metabolic rates in brain and heart
(3,4).
A three-compartment model has been found to be appro
priate to describe cerebral glucose transport and phosphory
lation by FDG PET (2). The model is shown in Figure 1. It
comprises one extracellular and two intracellular compart
ments. Four parameters characterize the exchange of FDG
between the three compartments. K1 (mUg/mm) describes
the clearance of FDG from the extracellular compartment
into the cell, and k2 (min') describes the transport rate of
unphosphorylated FDG from the cell back to the extracellu
lar compartment. The intracellular metabolism of FDG is
characterized by the rate constants k3 (min 1) for phosphor
ylation to FDG-6-P and k@(min@) for dephosphorylation.
Here we test the validity of this three-compartment model
of cerebral FDG metabolism for measurements of glucose
transport and phosphorylation in human skeletal muscle. A
measurement protocol is developed and optimized using
computer simulations with particular reference to plasma
input sampling and tissue sampling rates. The influence of
the fractional volume of the tissue region on the correctness
of the determined model parameters is investigated in detail.
Noise is not considered in the simulations. The reason for the
omission of noise is that the noise in the tissue data, that is,
the major noise component, can hardly be estimated cor
rectly because of its multiple causes, such as PET camera
parameters, count statistics, image reconstruction and image
PET with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) is used for
quantifyingglucosemetabolismin brainand myocardiumin vivo.
We developedand validateda similar procedurefor the quantifi
cation of the two initial steps of glucose metabolism in skeletal
muscle in vivo. Methods: The measurementprotocol was first
optimizedby computersimulations.In additionto the accuracyin
sampling plasma input and tissue time-activity curves, precise
determinationofthe fractionalbloodvolume,that is, the extracel
lular tissue volumefraction,playsa key role in correctnessof the
determinedmodelconstants.The optimizedprotocolwas subse
quently used to estimate transmembrane muscular glucose
transport and hexokinase activity in six human subjects with
normal or altered glucose utilization. PET was performed during
the steady state of an euglycemic hyperinsulinemic clamp.
Results:Athree-compartmentmodelprovidesa betterdescnp
tion of the experimental data than a two- or four-compartment
model. Glucose clearance from the extracellular compartment
intothe skeletalmusclecell (K1) rangesfrom 0.024 to 0.093
mUg/mm. The intracellular glucose phosphorylation rate (k3)
vanes between 0.030 and 0.142 min1. The regional muscular
glucose utilization, as calculated from the determined model
parameters, lies between 10.7 and 83.3 pmovkg/minand corre
lates with the whole-body glucose utilization as independently
determined(R2= 0.83; P s 0.01).Conclusion: Wedemonstrate
by computersimulationsthat a three-compartmentmodelcan be
used to characterizethe first two steps of glucose metabolismin
skeletal muscle. An optimized measurementprotocol is devel
oped and applied to experimental data. This experimental ap
proachshouldbe appropriateto testwhetherglucosetransport
orhexokinaseactivityisalteredindisordersofmuscularglucose
utilization.
Key Words: glucosemetabolism;skeletalmuscle;FDG PET;
hexokmnase;glucosetransport;PET
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three-compartment model and previously reported values for K1,k2
and k3 determined in skeletal muscle tissue by FDG PET (7â€”9)
(Table 1).The rate constant k.@,indicating the dephosphorylation of
FDG-6-P, was set to zero because it is negligible for times up to 45
mm postinjection (8,10). The fractional volume (FV), which
reflects the volume within the muscle tissue that contains extracel
lular but not intracellular tracer activity, was fixed to 3.5% as
measured by PET with â€˜50-CO(11). The time t@describes the time
difference between the appearance of the injection bolus in the
sampled plasma input and the muscle tissue that is measured in the
PET scanner. The time t@was set to 0.0 s in the simulations of the
influences of input and tissue sampling and of Pt.
Determination of the Compartment Model Parameters. The
parameters K1, k2, k3, Pt and t@were determined by nonlinear least
square fits (5). All data points received the same statistical weight
in the fitting procedure. The residual sum of squares (x2) reflecting
the sum of the squared differences between the simulated and the
fitted tissue time-activity curve was calculated from the fit data as a
measure of fit quality (5).
Results of the Simulations. To investigate the influence of the
input sampling on the determination of the model parameters, the
time intervals between the samples of G were systematically
prolonged. The input sampling schedules at a given sampling
interval were selected in a way that the characterization of the bolus
became as bad as possible (Fig. 2). The corresponding data are
given in Table 2. These reduced sampling rates lead to incomplete
descriptions of G during the bolus passage. As a consequence, the
determined model parameters deviate from the correct values.
Especially the parameters K1, k2, Pt and t@show significant
deviations from the correct values at sampling rates of one sample
every 20 5or longer. At sampling rates up to one sample every 60 s,
the quality of the determined model parameters is improved if
parameter Pt or t0 is fixed to the predefined values of the
simulations. If 0 is sampled every 120 s, the fit cannot be stabilized
by fixing Pt or t@.Sampling at rates of one sample every 15 s or
faster leads to stable determinations of all model parameters with
deviations below 5% compared with the correct values.
To determine the influence of the tissue sampling rate on the
determination of the model parameters, we reduced the data points
of the tissue time-activity curve during the initial 5 mm of the study
(Table 3). G(t) was used for the determination of the model
parameters. Sampling tissue data during the bolus transit at time
frames of 120 s or longer leads to incorrect values for the
parameters K1,k2and k3.The fit results can be stabilized by fixing
the delay time t0or Pt to the correct values. Tissue sampling with
an initial frame duration up to 90 s gives stable and correct
determinations of all parameters.
The influence of an incorrectly fixed Pt or t@on the rate
constants was simulated by fixing Pt to values between 0% and
5% (Fig. 3) and by fixing t@to values from â€”30to 40 s (Fig. 4). 0
and the continuous tissue time-activity curve were used for these
simulations. These fit results and the values of x2 were compared
with model fits with Pt or@ fixed to the correct values. The
simulations show the impact of an incorrectly predefined Pt or t@
on the model parameters. The parameters K1, k2 and k3 show
significant deviations from the correct values; k2 reacts the most
sensitively to false values for Pt and t@,with deviations up to 400%
from the correct values. The best fit quality as documented by the
lowest value for x2 is achieved with the correct values for Pt
and t@.
FIGURE1. Three-compartmentmodelofFOGmetabolism.
filtering. Finally, experimental data from human subjects
with normal or pathologic muscular glucose metabolism are
used to demonstrate the plausibility of the model.
MATERIALS AND METHODS
Simulations
Generation of the Input Function and lissue Data. The kinetic
parameters of a compartment model are conventionally determined
from the plasma input function and the tissue time-activity curve
measured by PET (5).
As a first component of the simulations, we generated an input
function and the corresponding tissue time-activity curve. On the
basis of this generated data, we then determined the impact of
variations in input and tissue sampling rates on the accuracy of the
determined rate constants.
The input function 0 was generated using a multiexponential
equation:
G(t) = [a1(t â€”t1) â€”a2 â€”a3]eb(t_tI) + a2et@2(tt1)
+ a3e@@3@t). Eq. 1
G is a function of the time t, which is characterizedby a fast
exponential decrease after the injection, due to diffusion of the
tracer in the blood and two exponential terms describing the slow
decrease caused by metabolism and excretion (6). 0 starts with the
injection of the tracer and is calculated until 45 mm postinjection.
Gis settozerofortimest t1,wheret1expressesthetimebetween
the injection and the appearance of the tracer in the plasma
samples. The parameters a1, a2, a3, b1, b2, b3 and t1 of 0 were
defined according to a multiexponential fit of actually measured
plasma input data from a healthy human subject (Table 1).
The tissue time-activity curve was calculated from G using a
TABLE 1
Parameters of Generated Input Function G and Generated
Tissue lime-Activity Curve
ValueParameter Unit
ti0.467mma1377.40kBq/mLfmina211.10kBq/mLa33.70kBqImLb13.00min1b20.18min1b30.015min1K10.04mUg/mmk20.15min1k30.09min1k40.00min1FV3.50%
FV = fractional volume.
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Sampling
intervalFixedparametersK1(mUJg/min)SDk2 (min1)SDk3 (min1)SDFV (%)SDto(s)SDx2G(t)
continuousâ€”0.0400.1500.0903.500.00.0045
sâ€”0.040<0.0010.151<0.0010.090<0.0013.510.000.0<0.010.00310
Sâ€”0.039<0.0010.1400.0030.0870.0023.620.020.80.1196.015
Sâ€”0.041<0.0010.1550.0020.0900.0013.640.01â€”1.80.1133.320
sâ€”0.038<0.0010.1290.0050.0830.0033.770.031.70.2612.620
sFV0.040<0.0010.1560.0050.0930.0033.50(f)0.90.2849.320
sto0.039<0.0010.1460.0060.0900.0043.570.030.0(f)960.520
sFV,to0.040<0.0010.1540.0060.0930.0043.50(f)0.0(f)985.230
sâ€”0.033<0.0010.0930.0110.0730.0094.150.098.90.54,226.230
sFV0.038<0.0010.1500.0140.0970.0093.50(f)6.20.5532.130
sto0.0410.0010.1860.0240.1080.0123.060.110.0(f)961.030
sFV,to0.0370.0010.1310.0160.0870.0113.50(f)0.0(f)9,091.260
sâ€”0.0290.0010.0470.0140.0510.0177.100.1715.30.89,780.260
sFV2.21013.8200.4420.0280.3930.0223.50(f)17.64.816,700.060
sto0.0450.0030.2090.0500.1150.0204.740.250.0(f)18,818.060
sFV,to0.0370.0010.1310.0830.2040.0173.50(f)0.0(f)19,491.0120
sâ€”0.0270.0030.0270.0230.0630.0381 7.000.801 9.51.6136.0120
sFV12.0082.0075.00511.000.1090.0083.50(f)19.55.0337.0120
sto6.0015.0012.0021.000.0200.04 â€”58.00125.000.0(f)337.0120
sFV, to0.4200.1502.4001.0000.1000.0103.50(f)0.0(f)829.0FV
â€”fractionaIvolume;f =parameterfixed.
50
G(t)
..*.. lOs
â€”4-. 20s
..*.. 30s
â€”@0â€”- $0 s
@40
@:30
E
.@0.
FIGURE2. GeneratedinputfunctionG(t)
and input curves with reduced data sam
pling.Samplinginputcurveat intervalsof
20 s or longer leads to incomplete character
izationof boluspassage.
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Experiments
Subjects. Six male human subjects with normal or pathologic
glucose utilization were studied after an overnight fast. Three
volunteers had type 2 diabetes (nonâ€”insulin-dependentdiabetes
mellitus [NIDDM]), 1 volunteer had been immobilized for 6 wk
before the study as a result of severe coronary artery disease with
cardiac decompensation and 2 volunteers were healthy (Table 4).
Antidiabetic drugs and @3-blockerswere discontinued the day
before the experiment. Patients under insulin substitution did not
receive insulin on the day of the experiment. The study protocol
was approved by the ethics commission of the Heinrich-Heine
University of DÃ¼sseldorfand by the local government regarding
the radiation exposure. All subjects gave written informed consent
before the examinations.
Euglycemic-Hyperinsulinemic Clamp. To achieve stable meta
bolic conditions during the PET measurements, the glucose metabo
lism was stabilized by an euglycemic-hyperinsulinemic clamp,
referred to as the â€œclampâ€•(1). Insulin (Velasulin Human; Novo
Nordisk, Mainz, Germany) was infused intravenously at a constant
rate (0.1 IU insulin/[kg body weight]/h). Glucose infusion was
adjusted to blood glucose levels that were measured every 5 mm to
reach steady-state blood glucose levels of 80 mg/dL. The steady
state condition with stable blood glucose levels at constant glucose
infusion rates was achieved 60â€”120mm after the start ofthe insulin
infusion, depending on the glucose level of the volunteer after
fasting. The whole-body glucose utilization (wbGU) was calcu
lated from the average glucose infusion rate (GI) and the body
TABLE2
Simulations: Influence of Input Sampling Interval on Fit Parameters K1, k2, k3, FV and t@
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Sampling
intervalFixedparametersK1(mUg/mm)SDk2 (min1)SDk3 (min1)SDFV (%)SDto(s)SDx2G(t)
continuousâ€”0.0400.1500.0903.500.00.0045
Sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.7<0.010.00310
Sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.0<0.010.00215
sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.0<0.010.00220
sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.0<0.010.00230
sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.0<0.010.00260
sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.00.100.00290
Sâ€”0.040<0.0010.150<0.0010.090<0.0013.480.020.60.500.00290
Sâ€”0.041<0.0010.1610.0020.925<0.0013.5(f)37.10.200.43490
sâ€”0.040<0.0010.150<0.0010.090<0.0013.50<0.010.0(f)0.00290
sâ€”0.040<0.0010.150<0.0010.090<0.0013.5(f)0.0(f)0.002120
Sâ€”0.039<0.0010.1480.0030.095<0.0014.490.2145.21.300.092120
sFV0.041<0.0010.1580.0010.092<0.0013.5(f)33.60.200.162120
sto0.040<0.0010.150<0.0010.090<0.0013.50<0.010.0(f)0.002120
sFV,to0.040<0.0010.150<0.0010.090<0.0013.5(f)0.0(f)0.0021
80 sâ€”0.0220.0580.01 90.41 60.0600.7781 .293.54528.51 1.509930.8 0180sFV0.0410.0460.1450.4240.0910.1423.5(f)502.1101. 09942.000180
sto0.040<0.0010.150<0.0010.090<0.0013.440.060.0(f)0.002180
sFV,to0.040<0.0010.150<0.0010.090<0.0013.5(f)0.0(f)0.002240
sâ€”0.038<0.0010.1400.0040.0960.0025.140.5327.19.000.002240
sFV0.040<0.0010.150<0.0010.090<0.0013.5(f)1 .11.300.002240
sto0.040<0.0010.151<0.0010.090<0.0013.420.090.0(f)0.002240
sFV,to0.040<0.0010.150<0.0010.090<0.0013.5(f)0.0(f)0.002300sâ€”0.0470.1140.1720.2310.0760.274â€”1.16100.28â€”29.21307.300.084300
sFV0.040<0.0010.150<0.0010.090<0.0013.5(f)â€”1.61.700.002300
sto0.040<0.0010.151<0.0010.090<0.0013.390.110.0(f)0.002300
sFV,to0.040<0.0010.150<0.0010.090<0.0013.5(f)0.0(f)0.002FV
= fractionaI volume; f =parameter fixed.
TABLE 3
Simulations:InfluenceofTissueSamplingIntervalonFitParametersK1, k2,k3,FVandt@
weight (BW) during the steady state of the clamp: the fasting state before initialization of the clamp and every 30 mm
during the steady state (Table 4). After FDG PET, the insulin
wbGU = 0! x BW'. Eq. 2 infusion was terminated, and the glucose infusion rate was
increased twofold until the patients reached their baseline blood
Blood for determination of serum glucose and insulin was drawn glucose level. Patients were released after an observation time of
from an arterialized hand vein. Insulin levels were determined in 60 mm.
FIGURE3. SimulationofinfluenceofFV
onfit. Parameterst@,K1, k2andk3show
significant deviationsfrom correct values if
FV is fixed incorrectly. Increased values of
x2indicater ducedfitqualityifFVisfixedto
incorrectvalues.
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PlasmaPlasmaPlasmainsulinBody
massglucoseinsulinsteadySubjectAgeindexAntidiabeticfastingfastingstateno.(y)(kg/rn2)Diagnosisdrugs
(dose/d)(mmol/L)(pU/mL)(pU/mL)15334.9HealthyNone5.44117924028.9HealthyNone6.1176735926.8CAD,
6-wkimmobilizationNone4.8358246337.7Type
2 diabetes for 9 yInsulin 24lU6.67127654830.9Type
2 diabetesfor4 yAcarbose 50mg8.94119365831.3Type2diabetesfor27ylnsulin4l
lU9.39978CAD
= coronary arterydisease.
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FIGURE4. Simulationofinfluenceoftime
delay to on fit. Model parameters K1, k2, k3
and FV show significant deviations from
correctvaluesif t@is fixedincorrectly.In
creased values of x2 indicate reduced fit
quality if t@is fixed to incorrectvalues.
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PET After the clamp had reached the steady state, the midthigh
region of the patient was positioned in the PET scanner (PET
Scanner, Type GE-4096 WB 7). Transmission data for attenuation
correction were acquired by applying a @Ge-pinsource (5 X 106
counts per slice).
FDG was synthesized according to the method described by
Hamacher et al. (12) with a radiochemical purity > 98%. Intrave
nous injections of 370 MBq (10 mCi) FDG were administered at a
constant rate within 10 s, followed by a flush of 20 mL physiologic
saline. Dynamic measurement of emission data started with the
injection of FDG. The dynamic protocol included 26 serial PET
images within a total time of45 mm: 1 X 30 s, 12 X 5 s, 3 X 10 s,
4 X 30 5, 1 X 60 5 and 8 X 300 s. The initial 30-s interval was
chosen to skip the time delay between the intravenous injection and
the appearance of the tracer in the femoral arteries. To allow
determination of the input function, blood was sampled from an
artenalized hand vein (every 6 s until 2 mm postinjection, then
every 30 5 until 5 mm postinjection and every 300 s until 45 mm
postinjection). The plasma (0.5 mL) was measured in a well
counter to determine the input curve of FDG for the muscle tissue.
Images were reconstructed by filtered backprojection (Hanning
filter, filter width 5 mm, correction for scatter and randoms) with a
pixel size of 4 X 4 mm in a 128 X 128 matrix. Data for attenuation
correction were calculated from the transmission scans. A total of
six regions of interest (ROIs) of the entire thigh muscle under
exclusion of great vessels, bone and subcutaneous fat were defined
in both thighs in three transversal slices (size of each ROI about
600 pixels or 60 mL). Time-activity analysis of the dynamic PET
data was performed with decay-corrected data.
Fit of Rate Constants and Determination of Regional Glucose
Transport and Regional Muscular Glucose Utilization. The rate
constants K1, k2, k3 and k@were determined with the sampled
plasma input curve and the tissue time-activity curve from the PET
measurement by a nonlinear least square fit as previously de
scribed. The rate constant k@(rate of intracellular dephosphoryla
tion of glucose-6-phosphate [G-6-P]) was set to zero because the
values for k4 were smaller than the determined standard error of k@
in all subjects.
The regional muscular glucose transport (rOT) was calculated
from the transport constant K1 and the plasma glucose level (Gl@).
assuming identical affinities for FDG and glucose to the glucose
transporter by:
rGT = K1 X Gl@. Eq.3
The regional muscular glucose utilization (rGU) was determined
from the model parameters and the Gl@,with the lumped constant
TABLE4
Clinical Data and Parameters from Euglycemic Hyperinsulinemic Clamp
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-30 -20 -10 0 s(s) 10
Subject
no.Test criterionThree
compartment
modelTwo
compartment
modelDifferenceRelative
change
(+%)Ftest1Akaike
Schwarz133.4 139.61
80.6
190.947.2 51.335.4 36.778.5;
P <0.052Akaike
Schwarz220.7 229.1222.1 234.51
.4
5.40.6 2.42.4;
P >0.053Akaike
Schwarz67.7 72.795.6 104.627.9 31.941
.2
43.91
4.0; P <0.054Akaike
Schwarz144.7 152.0240.5 251.995.8 99.966.2 65.7156.5;
P <0.055Akaike
Schwarz60.0 64.679.4 88.119.4 23.532.3 36.412.7;
P<0.056Akaike
Schwarz247.3 255.3349.3 359.21
02.0
103.941
.2
40.7524.9;
P < 0.05
(LC) assumed to be 1.0 in muscle tissue (13) by:
K1 X k3
rGU= XG1 XLC'.
k2+k3@
The rGU is in accordance with the amount of glucose that is
phosphorylated intracellularly by the hexokinase.
StatisticalAnalysIs
The compartment model fits were tested by the Akaike informa
tion criterion (14), the Schwarz criterion (15) and the F statistic
(16). These test criteria are calculated from the x2 values of the fits
and include recognition of the number of compartments, fitted
parameters and data points.
The determined regional muscular glucose utilization was
correlated with the whole-body glucose utilization as measured
during the steady state of the clamp. Significance of the regression
between regional muscular and whole-body glucose utilization was
tested by the Student t test.
Valldfty of the Three-Compartment Model
To test the correctness of the three-compartment model of FDG
metabolism for skeletal muscle, additional parameter fits, applying
models with two or four compartments, were conducted in the six
studied subjects. The consideration of these compartment models is
caused by the following arguments: It is possible that FDG is
transported only from the extracellular compartment into the
skeletal muscle cell (K1) and back (k2) but is not metabolized inside
the muscle cell (as known for 3-o-methyl-glucose). On the other
hand, the transport step across the cell membrane or the phosphory
lation could be so fast that it cannot be mathematically isolated.
These situations are correctly described by a model with two
compartments. The model with an additional third tissue compart
ment (a total of four compartments) is tested because of the
possibility of a different biochemical behavior of FDG in muscle
tissue, for example, a further metabolization ofFDG-6-P within the
muscle cell or additional intermediate transport steps caused by a
delayed transport from the blood vessel into the intercellular space.
The four-compartment model includes two additional rate con
stunts compared with the three-compartment model. if the two
compartment model or the four-compartment model describes the
muscular FDG metabolism better, then fits that apply these models
should lead to superior fit qualities when compared with the
three-compartment model.
Eq 4 In five of the six subjects, the Akaike information criterion, the
Schwarz criterion and the F statistic show a significant superiority
of the three-compartment model compared with the model with
two compartments. In one subject, all three test approaches showed
no significant results, but there was a trend toward the superiority
of the three-compartment model (Table 5).
With a four-compartment model assumed, a unique fit solution
could not be found in any of the six subjects. It was not possible to
isolate mathematically a fourth compartment from the other three
compartments. This mathematical interdependence between two
compartments in all datasets indicates that muscular FDG metabo
lism is not described better by the four-compartment model
compared with the three-compartment model.
RESULTS
The results of the compartment fits in the six studied
subjects are given in Table 6. Values for the glucose
transport from the extracellular compartment into the cell
(K1)rangefrom0.024 to 0.093 mL/g/min.The rateconstant
for the transport from the cell back to the blood vessel (k2) is
in the range between 0.045 and 0.81 min 1; the intracellular
phosphorylation rate (k3) ranges from 0.030 to 0.142 min lâ€¢
The regional metabolic rate constant (KMRG1)and the re
gional muscular glucose utilization as calculated from the
determined model parameters show a significant linear
correlation (R2 = 0.83, P@ 0.01) (Table 7 and Fig. 5).
DISCUSSION
The data presented show by means of computer simula
tions and experiments that the initial two steps of muscular
glucose metabolism, namely, the glucose transport and the
intracellular phosphorylation, can be quantified with FDG
PETusing a three-compartmentmodel.
Our simulations show, in concordance with a previous
study, that insufficient determination of the plasma input and
tissue time-activity curves leads to incorrect values for all
TABLE 5
Tests for Fit Quality of Six Studied Subjects Applying Two- and Three-Compartment Models
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Subject
no.K1 (mL/g/min)k2 (min1)k@ (min1)FV (%)to(s)10.048
Â±0.0110.38 Â±0.150.091 Â±0.0200.9 Â±0.7â€”12.9 Â±8.020.046
Â±0.0150.21 Â±0.130.127 Â±0.0235.4 Â±1.70.0 Â±5.730.035
Â±0.0050.12 Â±0.020.030 Â±0.0051 .2 Â±0.3â€” 17.5 Â±3.840.093
Â±0.0030.81 Â±0.080.142 Â±0.0260.4 Â±0.4â€”0.2 Â±2.650.033
Â±0.0020.05 Â±0.020.064 Â±0.0132.5 Â±0.2â€”3.1 Â±0.560.024
Â±0.0020.38 Â±0.020.047 Â±0.0030.8 Â±0.3â€”22.9 Â±5.9Data
arefit resultÂ±SD.
RegionalRegionalmuscularmuscularWhole-bodyglucoseglucoseglucoseSubjecttransportutilizationutilizationno.(pmovkg/mmn)(pmovkg/mmn)(pmoVkg/min)1218.741.721.82220.783.332.93150.829.910.14355.453.225.15144.878.724.4697.210.79.2
TABLE 6
Fit Results of Six Studied Subjects
model parameters (5). In our simulations, the model param
eters are incorrectly determined at input sampling intervals
longer than 15 s. The duration of the initial tissue sampling
interval can be significantly longer; intervals up to 90 s lead
to correct fits of the simulated data. The influence of 1W on
the model parameters and the impact of using fixed values
for Pt or t@to stabilize the fit have not been reported
previously. Fixing P1 or t@to incorrect values seriously
influences the model parameters, as shown by our simula
tions. In the six studied subjects, Pt ranges from 0.4% to
5.4% and to from â€”22.9to 0.0 s. As a consequence, 1W and
to are parameters that cannot be fixed before the model fit
because the correct values are unknown and have to be
determined individually. An alternative way is measuring
the regional muscular Pt under clamp conditions by â€˜50-CO
PET (11).
A comparison of the statistical validity of fits in models
with two, three and four compartments shows that the
three-compartment model gives the best description of the
FDG metabolism in the skeletal muscle and should be
applied for quantification of muscular glucose metabolism.
The stable fit results in all studied subjects and the signifi
cant correlation between regional muscular glucose utiliza
tion and whole-body glucose utilization provide further
evidence that the three-compartment model is adequate for
the description of muscular FDG metabolism. This three
compartment model has been established and validated for
TABLE 7
Results of Six Studied Subjects
quantification of the rate constants of glucose transport and
glucose phosphorylation in the brain (2). It is applied in
tumor tissue (1 7) and skeletal muscle tissue (8,9), but its
validity has not been tested for skeletal muscle.
In all six studied subjects, the determined muscular model
constants K1, k2 and k3 and the glucose metabolic rate KMRGI
were in the range of muscular values presented by Kelley et
al. (8) for healthy and diabetic volunteers. Kelley et al. (8)
determined the model constants in skeletal muscle during an
euglycemic hyperinsulinemic clamp as well as in the fasting
state. They found significant increases in k3 and regional
muscular glucose utilization at insulin stimulation in all
studied subgroups (diabetic, lean nondiabetic and obese
nondiabetic) and increased values for K1 under insulin
stimulation only in the lean nondiabetic subgroup. In the
other two subgroups, no significant effect of insulin on K1
was observed. Under insulin stimulation in all subgroups, k2
remained unchanged. Kelley et al. (8) also found a signifi
cant correlation between muscular glucose utilization and
whole-body glucose utilization. Selberg et al. (9) presented
similar values in the skeletal muscle of healthy persons
during clamp conditions for K1 and the regional glucose
utilization, but k2 and k3 were clearly lower. In both studies,
P1 andthedelaytime t<@arenot mentioned.It is possiblethat
the omission of these parameters in the study by Selberg et
al. (9) caused the differences in our results as well as those of
Kelley et al. (8). Hawkins et al. (16) showed that the
disregard of P1 leads to significant differences in the rate
constants in the brain.
Because the fitted parameters are in good concordance in
all six tissue ROIs in every subject, noise is not a major
problem in the proposed measurement protocol. Neverthe
less, the longest frame duration that allows stable fits should
be selected to minimize statistical noise.
Compared with FDG PET studies of the brain, the
muscular parameters K1, k2 and k3 are in the same range
(16). Quantification of regional glucose utilization in the
myocardium by FDG PET revealed values (842.8 Â±91.1
pmol/kg/min) that were tenfold higher than in the femoral
muscle (83.9 Â±10 @tmoVkgImin)(18). In our data, regional
muscular glucose utilization ranges between 10.7 and 83.3
GLUCOSEMETABOLISMOF SKELETALMUSCLE â€¢Reinhardt et al. 983
35
.
30
â€˜C
.@ 25
@!20
0
@b5
@ 10
.
.
LInear RegressIon
y@ 0.30x + 5.77
R2@0.83p@0.0b
5
0 10 20 30 40 50
rGU(pmol *kg1 . mm'1)FIGURE5. Linearregressionbetween
rGUand wbGUas reportedin Table7.
p.tmol/kg/min. The differences in the glucose utilization of
skeletal muscle can be explained by the different degree of
insulin stimulation, dissimilar glucose metabolism in white
and red muscle fibers and individual parameters of the
studied subjects, such as insulin resistance, age and body
mass index in this study.
CONCLUSION
The data presented support the validity of the FDG model
for determinations of glucose transport and phosphorylation
in skeletal muscle. It is planned to apply the model for
quantification of muscular glucose transport and phosphory
lation in more patients with NIDDM or others with reduced
glucose tolerance. Patients with NIDDM develop a muscular
insulin resistance that is characterized by reduced muscular
glucose utilization in general and a reduction of glycogen
synthesis in particular (19). Similarly, the concentration of
G-6-P, an intermediate of the intracellular glucose metabo
lism, is reduced (20). Several hypotheses may explain these
findings: (a) The transport of glucose across the cellular
membrane is impaired; (b) the intracellular phosphorylation
of glucose to G-6-P is reduced; and (c) the degradation of
G-6-P through the glycolysis and/or pentose phosphate
pathway is increased. Kelley et al. (8) showed that the
intracellular muscular glucose phosphorylation rate (k3) and
the regional muscular glucose utilization are reduced in
patients with NIDDM, whereas the glucose transport con
stant (K1) is not altered significantly compared with obese
nondiabetic subjects. Further FDG PET studies shall provide
more data on glucose transport and phosphorylation in
insulin-resistant subjects.
ACKNOWLEDGMENT
This study was supported by a grant from the Deutsche
@orschun@s@emeinschaft(DFG), project B3 of Sonderforsch
REFERENCES
I . DeFronzo RA, Gunnarsson R, BjÃ¶rkman 0, Olsson M, Wabren J. Effects of
insulin on peripheral and splanchnic glucose metabolism in nonâ€”insulin
dependent (type H) diabetes mellitus. J Cliii Invest. 1985:76:149â€”155.
2. PhelpsME,Huang,SC, HoffmannEJ, SelinC, SokoloffL, KuhIDE.Tomo
graphic measurement of local cerebral glucose metabolic rate in humans with
(F-18)2-fluoro-2-deoxy-D-glucose: validation ofmethod. Ann Neumi. 1979:6:371â€”
388.
3. Maziotta JC, Phelps ME. Positron emission tomography studies of the brain. In:
Phelps M, Maziotta J, Schelbert H, eds. Positron Emission Tomography and
Autoradiography: Principles and Applications for the Brain and Heart. New
York, NY: Raven: 1986:493â€”579.
4. Schelbert HR. Schwaiger M. PET studies of the heart. In: Phelps M, Maziotta J,
Schelbert H, eds. Positron Emission Tomography and Autoradiography: Prin
ciples and Applications for the Brain and Heart. New York, NY: Raven:
1986:581â€”661.
5. Mazoyer BM, Huesman RH, Budinger TF, Knittel BL. Dynamic PET data
analysis. J ComputAssist Tonwgr 1986:10:645â€”653.
6. Feng D, Wang X, Yan H. A computer simulation on the input function sampling
schedules in tracer kinetic modeling with positron emission tomography (PET).
Comput Methods Programs Biomed. 1994:45:175â€”186.
7. Frey LD, Locher J1'h, Hrycaj P. et al. Bestimmung der regionalen Glukose
Metabolisierungsrate der Lumbalmuskulatur bei Patienten mit generalisierter
Tendomyopathie (GTM) mittels dynamischer â€˜8F-FDG-PET.Z Rheumatol. 1992:
51:238â€”242.
8. Kelley DE, Mintun MA, Watkins SC, et al. The effect of nonâ€”insulin-dependent
diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal
muscle. J Clin Invest. 1996:97:2705â€”2713.
9. Selberg 0. Burchert W, van den HoffJ, et al. Insulin resistance in liver cirrhosis. J
Clin Invest. I993:91:1897â€”1902.
10. Lucignani G, Schmidt KC, Moresco RM, et al. Measurement of regional cerebral
glucose utilization with fluorine-I 8-FOG and PET in heterogeneous tissues. J
NucI Med. 1993:34:360â€”369.
11. Raitakari M, Knuuti Mi, Ruotsalainen U, et al. Insulin increases blood volume in
human skeletal muscle: studies using [Â°OJCOand positron emission tomography.
Am J Physiol. 1995:269:El000â€”E1005.
12. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no
carrier-added 2-['8F]fluoro-2-deoxy-D-glucose using aminopolyether supported
nucleophilic substitution. J NucI Med. 1986:27:235â€”238.
13. Voipio-Pulkki L-M, Nuutila P. Knuuti MJ, et al. Heart and skeletal muscle glucose
disposal in type 2 diabetic patients as determined by positron emission tomogra
phy. J Nuci Med. I993:34:2064â€”2067.
14. Akaike H. A new look at the statistical model identification. IEEE Trans Automat
ContrI974:AC-I9:716â€”723.
15. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978:6:461â€”564.ungsbereich 35 1.
984 THEJOURNALOFNUCLEARMEDICINEâ€¢Vol. 40 â€¢No. 6 â€¢June 1999
60 70 80
16. Hawkins RA, Phelps ME, Sung-Cheng H. Effects of temporal sampling, glucose
metabolic rates, and disruption of the blood-brain barrier on the FDG model with
and without a vascular compartment: studies in human brain tumors with PET. J
Cereb Blood Flow Metab. 1986:6:170â€”183.
17. Wu H-M, Huang S-C, Choi Y, Hoh CK, Hawkins RA. A modeling method to
improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor
tissue.JNucl Med.1995:36:297â€”306.
18. Nuutila P. Knuuti MJ, Heinonen OJ, et al. Different alterations in the insulin
stimulated glucose uptake in the athlete's heart and skeletal muscle. J Clin invest.
1994:93:2267â€”2274.
19. Shulman GI, Rothman DL Jue T, Stein P. DeFronzo RA, Shulman RG.
Quantitation of muscle glycogen synthesis in normal subjects and subjects with
nonâ€”insulin-dependent diabetes by â€˜@Cnuclear magnetic resonance spectroscopy.
NEngIJ Med. 1990:322:223â€”228.
20. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic resonance
measurements of muscle glucose-6-phosphate. J Clin invest. 1993:89:1069-1075.
GLUCOSE METABOLISM OF SKELETAL MUSCLE â€¢Reinhardt et al. 985
